Skip to contentV
Vaxcyte, Inc.
V
PCVXVaxcyte, Inc. Released Mar 29, 2021, after the close
10-K filed Mar 29, 2021, 88 days after period end · 0001564590-21-016110
Q4 2020 · 10-K
Revenue—
Net Income-$20.74M-$20.74MN/M vs Q4 2019N/M vs Q3 2020 EPS Diluted
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaxcyte, Inc. · CIK 1649094 · Engraved from SEC EDGAR
-$0.41-$0.41N/M vs Q4 2019N/M vs Q3 2020 Operating Income-$19,453,000N/M Operating Cash Flowderived-$10,768,000N/M Free Cash Flowderived-$11,490,000N/M ended Dec 31, 2020 · filed Mar 29, 2021 · 88 d after period end
21.5% from the close of Mar 26, 2021 to the close of Mar 30, 2021, the first after the release.
after the close$23.76$18.66 Jan 29Mar 29May 14